There are 2789 resources available
1470P - Oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence
Presenter: Thatcher Heumann
Session: ePoster Display
1471P - Overall survival by BRCA and ATM mutation status in patients with metastatic pancreatic cancer: Findings from the PRIOR-2 study
Presenter: Gboyega Adeboyeje
Session: ePoster Display
1472P - Circulating tumor DNA in unresectable pancreatic cancer is a strong predictor of response to first-line therapy: The KRASCIPANC study
Presenter: Camille Evrard
Session: ePoster Display
1473P - Gender differences in treatment allocation and survival in a real-world metastatic pancreatic cancer cohort
Presenter: Esther Pijnappel
Session: ePoster Display
1474P - Patient characteristics and treatment patterns in patients with metastatic pancreatic cancer by BRCA/ATM status in the PRIOR-2 study
Presenter: Maria Sierra
Session: ePoster Display
1475P - Results of a randomized, double-blind, placebo-controlled, phase II study of gemcitabine and nab-paclitaxel ± olaratumab in treatment-naïve patients with unresectable metastatic pancreatic cancer
Presenter: Faithlore Gardner
Session: ePoster Display
1630P - The impact of the COVID-19 outbreak on surgical site infections in elective colorectal cancer surgery: One potential benefit of the pandemic?
Presenter: Francesk Mulita
Session: ePoster Display
1631P - Evaluation of the socio-sanitary and emotional impact caused by SARS-CoV-2 in a Spanish cohort of cancer patients after the second pandemic wave
Presenter: Daniel Herrero Rivera
Session: ePoster Display
1632P - At home androgen deprivation therapy for patients with prostate cancer during the COVID-19 pandemic. One center experience
Presenter: Tamar Esakia
Session: ePoster Display
1633P - Why do cancer clinical trials (CT) discontinue prematurely in the era of COVID-19?
Presenter: Giovanni Maria Iannantuono
Session: ePoster Display